

VRL/SEC/EXCHANGE/2026-27

22.05.2026

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai Script Code: 526953
---	--

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref.: Venus Remedies receives Saudi FDA approval for Plerixafor — its first Marketing Authorization for the specialty oncology therapy globally

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith a press release being issued by the Company on the captioned subject.

Thanking you
Yours faithfully,
for **VENUS REMEDIES LIMITED**


Neha
(Company Secretary)
M. No. F8374

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





PRESS RELEASE

Venus Remedies receives Saudi FDA approval for Plerixafor — its first Marketing Authorization for the specialty oncology therapy globally

- First Marketing Authorization secured by Venus Remedies for Plerixafor in any market
- Advances the company's shift into higher-value specialty injectables across regulated markets
- Plerixafor is a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma

India, May 22, 2026: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world's ten largest fixed-dosage injectable manufacturers, has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor.

This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with differentiated therapies in regulated markets.

Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in. The Kingdom has the largest pharmaceutical market in the GCC and one of the fastest-growing oncology and transplant infrastructures in the region. Plerixafor sits squarely in the kind of therapy class we are building our international portfolio around. These are specialty injectables where clinical complexity and regulatory rigor create durable demand. It is also a meaningful addition for haemato-oncology centers across Saudi Arabia, where stem cell transplantation volumes are rising."

"This approval reflects our continued shift toward differentiated specialty therapies in regulated markets and reinforces India's role as a credible supplier of complex injectables to demanding healthcare systems," he added.

The Saudi Arabian pharmaceutical market is projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033, a CAGR of 5.0%, driven by rising chronic disease prevalence and healthcare investment under Vision 2030. The GCC stem cell therapy market was estimated at USD 1.2 billion in 2024, with Saudi Arabia, the UAE, and Qatar as the principal markets.





Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, "Saudi Arabia is the most important commercial market in the GCC for specialty oncology, and this approval gives us a direct platform there. We will use it to build hospital partnerships and to anchor further specialty launches across the region. Regulatory and commercial work are tightly linked in markets like this, and the SFDA approval is evidence of both lines of execution working."

The approval enables Venus Remedies to commercialize Plerixafor 24mg/1.2ml in Saudi Arabia through its existing international business network, with a focus on tertiary oncology centers.

About Venus Remedies Ltd (venusremedies.com)

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β -lactam/ β -lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.

